Cancer Medicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=573717, encodeId=26d75e3717b9, content=我被拒稿了，很闹心，二修被拒稿的811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？811056778 2019-07-15 00:00:00 发表: 有被拒稿的吗？大家都under review 很久吗？, beContent=811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c2453714, createdName=123fdc7am51暂无昵称, createdTime=Tue Jul 16 00:00:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053539, encodeId=5e40105353926, content=审稿速度:6.0 | 投稿命中率:75.0 | 版面费用:3025.0 偏重的研究方向：肿瘤 经验分享：under review 的时间比较长，我的4个月。 然后3个reviwers中一个很mean，另外两个很nice。最后小修的时候直接没有返回第一个review的意见。 感觉过了第一次riview后就比较有希望，编辑整体对中国的作者还挺nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd391571598, createdName=cookie97_02, createdTime=Tue Sep 21 17:56:32 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861880, encodeId=5e738618805e, content=审稿速度:1.0 经验分享：杂志主编是杜克大学魏庆义教授，之前投过三次，有最后被专科顶级期刊（3.8分）接收的文章，每次都是投完第二天就显示under review，然后2-3周后reject且没有外审意见，这本杂志上面文章整体质量参差不齐，好几篇与外科相关的公共数据库文章硬伤很明显，但居然都能被接收，不知道是不是因为想赚取版面费，毕竟版面费很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470b5414019, createdName=ms8494960720180498, createdTime=Sun Jun 14 20:19:48 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589120, encodeId=91e55891204e, content=pending decision快2周了是还在找审稿人吗..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba91646015, createdName=凱当以慷, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887784, encodeId=bc3888e784c6, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：半年了，今天被接收，真的好激动, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66315412610, createdName=ms9000000365593010, createdTime=Wed Sep 23 22:03:59 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943952, encodeId=ebf8943952fc, content=Cancer Medicine期刊近5年发文量先下降再上涨，2016年仅有三百多篇，2017年有所缩篇至200篇+，2018年有大幅度扩篇发文量为590篇，2019年持续大幅度扩篇突破800篇+，2020年与2019年基本持平。其他信息：中国发文占比约为（51 %），去年国人发文占比为290/834(34.8%)。自引率 Cancer Medicine近五年自引率均控制在2.1%以下，2016年为1.3%，2017年为1.3%，2018年为1.9%，2019年自引率为2.1%，2020年自引率为0.8%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Sat Feb 27 15:29:10 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588880, encodeId=ed82588880e7, content=请问pending editor assignment是啥，要持续多久137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, beContent=137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803209, encodeId=447a803209d1, content=刚中一个不容易！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sat Jul 18 18:33:54 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801120, encodeId=8d69801120c5, content=共同通讯怎么选择呀？网站上面只能选一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhNNGfbGSN7wmcNz2pib2uha6Ao0k08eBAYg1j1K239eYgsrXibWPvG9SMo9UY32HXlSHgibarsFKkQ/132, createdBy=8b052569732, createdName=305263495_85429342, createdTime=Fri Jul 03 22:54:07 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589182, encodeId=3c765891821f, content=我都快两月了还是under reviewCXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…CXK 2020-04-11 00:00:00 发表: 40天了还是分配编辑有比我还久的嘛…, beContent=CXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0635277719, createdName=148378a5m85暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=)]

2019-07-16 123fdc7am51暂无昵称

我被拒稿了，很闹心，二修被拒稿的811056778 2019-07-15 发表::
有被拒稿的吗？大家都under review 很久吗？811056778 2019-07-15 00:00:00 发表:
有被拒稿的吗？大家都under review 很久吗？

811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？

62 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573717, encodeId=26d75e3717b9, content=我被拒稿了，很闹心，二修被拒稿的811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？811056778 2019-07-15 00:00:00 发表: 有被拒稿的吗？大家都under review 很久吗？, beContent=811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c2453714, createdName=123fdc7am51暂无昵称, createdTime=Tue Jul 16 00:00:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053539, encodeId=5e40105353926, content=审稿速度:6.0 | 投稿命中率:75.0 | 版面费用:3025.0 偏重的研究方向：肿瘤 经验分享：under review 的时间比较长，我的4个月。 然后3个reviwers中一个很mean，另外两个很nice。最后小修的时候直接没有返回第一个review的意见。 感觉过了第一次riview后就比较有希望，编辑整体对中国的作者还挺nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd391571598, createdName=cookie97_02, createdTime=Tue Sep 21 17:56:32 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861880, encodeId=5e738618805e, content=审稿速度:1.0 经验分享：杂志主编是杜克大学魏庆义教授，之前投过三次，有最后被专科顶级期刊（3.8分）接收的文章，每次都是投完第二天就显示under review，然后2-3周后reject且没有外审意见，这本杂志上面文章整体质量参差不齐，好几篇与外科相关的公共数据库文章硬伤很明显，但居然都能被接收，不知道是不是因为想赚取版面费，毕竟版面费很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470b5414019, createdName=ms8494960720180498, createdTime=Sun Jun 14 20:19:48 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589120, encodeId=91e55891204e, content=pending decision快2周了是还在找审稿人吗..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba91646015, createdName=凱当以慷, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887784, encodeId=bc3888e784c6, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：半年了，今天被接收，真的好激动, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66315412610, createdName=ms9000000365593010, createdTime=Wed Sep 23 22:03:59 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943952, encodeId=ebf8943952fc, content=Cancer Medicine期刊近5年发文量先下降再上涨，2016年仅有三百多篇，2017年有所缩篇至200篇+，2018年有大幅度扩篇发文量为590篇，2019年持续大幅度扩篇突破800篇+，2020年与2019年基本持平。其他信息：中国发文占比约为（51 %），去年国人发文占比为290/834(34.8%)。自引率 Cancer Medicine近五年自引率均控制在2.1%以下，2016年为1.3%，2017年为1.3%，2018年为1.9%，2019年自引率为2.1%，2020年自引率为0.8%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Sat Feb 27 15:29:10 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588880, encodeId=ed82588880e7, content=请问pending editor assignment是啥，要持续多久137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, beContent=137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803209, encodeId=447a803209d1, content=刚中一个不容易！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sat Jul 18 18:33:54 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801120, encodeId=8d69801120c5, content=共同通讯怎么选择呀？网站上面只能选一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhNNGfbGSN7wmcNz2pib2uha6Ao0k08eBAYg1j1K239eYgsrXibWPvG9SMo9UY32HXlSHgibarsFKkQ/132, createdBy=8b052569732, createdName=305263495_85429342, createdTime=Fri Jul 03 22:54:07 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589182, encodeId=3c765891821f, content=我都快两月了还是under reviewCXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…CXK 2020-04-11 00:00:00 发表: 40天了还是分配编辑有比我还久的嘛…, beContent=CXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0635277719, createdName=148378a5m85暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=)]

2021-09-21 cookie97_02

审稿速度:6.0 | 投稿命中率:75.0 | 版面费用:3025.0
偏重的研究方向：肿瘤
经验分享：under review 的时间比较长，我的4个月。
然后3个reviwers中一个很mean，另外两个很nice。最后小修的时候直接没有返回第一个review的意见。
感觉过了第一次riview后就比较有希望，编辑整体对中国的作者还挺nice

28 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573717, encodeId=26d75e3717b9, content=我被拒稿了，很闹心，二修被拒稿的811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？811056778 2019-07-15 00:00:00 发表: 有被拒稿的吗？大家都under review 很久吗？, beContent=811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c2453714, createdName=123fdc7am51暂无昵称, createdTime=Tue Jul 16 00:00:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053539, encodeId=5e40105353926, content=审稿速度:6.0 | 投稿命中率:75.0 | 版面费用:3025.0 偏重的研究方向：肿瘤 经验分享：under review 的时间比较长，我的4个月。 然后3个reviwers中一个很mean，另外两个很nice。最后小修的时候直接没有返回第一个review的意见。 感觉过了第一次riview后就比较有希望，编辑整体对中国的作者还挺nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd391571598, createdName=cookie97_02, createdTime=Tue Sep 21 17:56:32 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861880, encodeId=5e738618805e, content=审稿速度:1.0 经验分享：杂志主编是杜克大学魏庆义教授，之前投过三次，有最后被专科顶级期刊（3.8分）接收的文章，每次都是投完第二天就显示under review，然后2-3周后reject且没有外审意见，这本杂志上面文章整体质量参差不齐，好几篇与外科相关的公共数据库文章硬伤很明显，但居然都能被接收，不知道是不是因为想赚取版面费，毕竟版面费很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470b5414019, createdName=ms8494960720180498, createdTime=Sun Jun 14 20:19:48 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589120, encodeId=91e55891204e, content=pending decision快2周了是还在找审稿人吗..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba91646015, createdName=凱当以慷, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887784, encodeId=bc3888e784c6, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：半年了，今天被接收，真的好激动, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66315412610, createdName=ms9000000365593010, createdTime=Wed Sep 23 22:03:59 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943952, encodeId=ebf8943952fc, content=Cancer Medicine期刊近5年发文量先下降再上涨，2016年仅有三百多篇，2017年有所缩篇至200篇+，2018年有大幅度扩篇发文量为590篇，2019年持续大幅度扩篇突破800篇+，2020年与2019年基本持平。其他信息：中国发文占比约为（51 %），去年国人发文占比为290/834(34.8%)。自引率 Cancer Medicine近五年自引率均控制在2.1%以下，2016年为1.3%，2017年为1.3%，2018年为1.9%，2019年自引率为2.1%，2020年自引率为0.8%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Sat Feb 27 15:29:10 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588880, encodeId=ed82588880e7, content=请问pending editor assignment是啥，要持续多久137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, beContent=137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803209, encodeId=447a803209d1, content=刚中一个不容易！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sat Jul 18 18:33:54 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801120, encodeId=8d69801120c5, content=共同通讯怎么选择呀？网站上面只能选一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhNNGfbGSN7wmcNz2pib2uha6Ao0k08eBAYg1j1K239eYgsrXibWPvG9SMo9UY32HXlSHgibarsFKkQ/132, createdBy=8b052569732, createdName=305263495_85429342, createdTime=Fri Jul 03 22:54:07 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589182, encodeId=3c765891821f, content=我都快两月了还是under reviewCXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…CXK 2020-04-11 00:00:00 发表: 40天了还是分配编辑有比我还久的嘛…, beContent=CXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0635277719, createdName=148378a5m85暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=)]

2020-06-14 ms8494960720180498

审稿速度:1.0
经验分享：杂志主编是杜克大学魏庆义教授，之前投过三次，有最后被专科顶级期刊（3.8分）接收的文章，每次都是投完第二天就显示under review，然后2-3周后reject且没有外审意见，这本杂志上面文章整体质量参差不齐，好几篇与外科相关的公共数据库文章硬伤很明显，但居然都能被接收，不知道是不是因为想赚取版面费，毕竟版面费很高。

54 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573717, encodeId=26d75e3717b9, content=我被拒稿了，很闹心，二修被拒稿的811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？811056778 2019-07-15 00:00:00 发表: 有被拒稿的吗？大家都under review 很久吗？, beContent=811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c2453714, createdName=123fdc7am51暂无昵称, createdTime=Tue Jul 16 00:00:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053539, encodeId=5e40105353926, content=审稿速度:6.0 | 投稿命中率:75.0 | 版面费用:3025.0 偏重的研究方向：肿瘤 经验分享：under review 的时间比较长，我的4个月。 然后3个reviwers中一个很mean，另外两个很nice。最后小修的时候直接没有返回第一个review的意见。 感觉过了第一次riview后就比较有希望，编辑整体对中国的作者还挺nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd391571598, createdName=cookie97_02, createdTime=Tue Sep 21 17:56:32 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861880, encodeId=5e738618805e, content=审稿速度:1.0 经验分享：杂志主编是杜克大学魏庆义教授，之前投过三次，有最后被专科顶级期刊（3.8分）接收的文章，每次都是投完第二天就显示under review，然后2-3周后reject且没有外审意见，这本杂志上面文章整体质量参差不齐，好几篇与外科相关的公共数据库文章硬伤很明显，但居然都能被接收，不知道是不是因为想赚取版面费，毕竟版面费很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470b5414019, createdName=ms8494960720180498, createdTime=Sun Jun 14 20:19:48 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589120, encodeId=91e55891204e, content=pending decision快2周了是还在找审稿人吗..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba91646015, createdName=凱当以慷, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887784, encodeId=bc3888e784c6, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：半年了，今天被接收，真的好激动, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66315412610, createdName=ms9000000365593010, createdTime=Wed Sep 23 22:03:59 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943952, encodeId=ebf8943952fc, content=Cancer Medicine期刊近5年发文量先下降再上涨，2016年仅有三百多篇，2017年有所缩篇至200篇+，2018年有大幅度扩篇发文量为590篇，2019年持续大幅度扩篇突破800篇+，2020年与2019年基本持平。其他信息：中国发文占比约为（51 %），去年国人发文占比为290/834(34.8%)。自引率 Cancer Medicine近五年自引率均控制在2.1%以下，2016年为1.3%，2017年为1.3%，2018年为1.9%，2019年自引率为2.1%，2020年自引率为0.8%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Sat Feb 27 15:29:10 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588880, encodeId=ed82588880e7, content=请问pending editor assignment是啥，要持续多久137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, beContent=137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803209, encodeId=447a803209d1, content=刚中一个不容易！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sat Jul 18 18:33:54 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801120, encodeId=8d69801120c5, content=共同通讯怎么选择呀？网站上面只能选一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhNNGfbGSN7wmcNz2pib2uha6Ao0k08eBAYg1j1K239eYgsrXibWPvG9SMo9UY32HXlSHgibarsFKkQ/132, createdBy=8b052569732, createdName=305263495_85429342, createdTime=Fri Jul 03 22:54:07 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589182, encodeId=3c765891821f, content=我都快两月了还是under reviewCXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…CXK 2020-04-11 00:00:00 发表: 40天了还是分配编辑有比我还久的嘛…, beContent=CXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0635277719, createdName=148378a5m85暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=)]

2020-04-17 凱当以慷

pending decision快2周了是还在找审稿人吗...

33 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573717, encodeId=26d75e3717b9, content=我被拒稿了，很闹心，二修被拒稿的811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？811056778 2019-07-15 00:00:00 发表: 有被拒稿的吗？大家都under review 很久吗？, beContent=811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c2453714, createdName=123fdc7am51暂无昵称, createdTime=Tue Jul 16 00:00:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053539, encodeId=5e40105353926, content=审稿速度:6.0 | 投稿命中率:75.0 | 版面费用:3025.0 偏重的研究方向：肿瘤 经验分享：under review 的时间比较长，我的4个月。 然后3个reviwers中一个很mean，另外两个很nice。最后小修的时候直接没有返回第一个review的意见。 感觉过了第一次riview后就比较有希望，编辑整体对中国的作者还挺nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd391571598, createdName=cookie97_02, createdTime=Tue Sep 21 17:56:32 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861880, encodeId=5e738618805e, content=审稿速度:1.0 经验分享：杂志主编是杜克大学魏庆义教授，之前投过三次，有最后被专科顶级期刊（3.8分）接收的文章，每次都是投完第二天就显示under review，然后2-3周后reject且没有外审意见，这本杂志上面文章整体质量参差不齐，好几篇与外科相关的公共数据库文章硬伤很明显，但居然都能被接收，不知道是不是因为想赚取版面费，毕竟版面费很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470b5414019, createdName=ms8494960720180498, createdTime=Sun Jun 14 20:19:48 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589120, encodeId=91e55891204e, content=pending decision快2周了是还在找审稿人吗..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba91646015, createdName=凱当以慷, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887784, encodeId=bc3888e784c6, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：半年了，今天被接收，真的好激动, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66315412610, createdName=ms9000000365593010, createdTime=Wed Sep 23 22:03:59 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943952, encodeId=ebf8943952fc, content=Cancer Medicine期刊近5年发文量先下降再上涨，2016年仅有三百多篇，2017年有所缩篇至200篇+，2018年有大幅度扩篇发文量为590篇，2019年持续大幅度扩篇突破800篇+，2020年与2019年基本持平。其他信息：中国发文占比约为（51 %），去年国人发文占比为290/834(34.8%)。自引率 Cancer Medicine近五年自引率均控制在2.1%以下，2016年为1.3%，2017年为1.3%，2018年为1.9%，2019年自引率为2.1%，2020年自引率为0.8%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Sat Feb 27 15:29:10 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588880, encodeId=ed82588880e7, content=请问pending editor assignment是啥，要持续多久137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, beContent=137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803209, encodeId=447a803209d1, content=刚中一个不容易！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sat Jul 18 18:33:54 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801120, encodeId=8d69801120c5, content=共同通讯怎么选择呀？网站上面只能选一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhNNGfbGSN7wmcNz2pib2uha6Ao0k08eBAYg1j1K239eYgsrXibWPvG9SMo9UY32HXlSHgibarsFKkQ/132, createdBy=8b052569732, createdName=305263495_85429342, createdTime=Fri Jul 03 22:54:07 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589182, encodeId=3c765891821f, content=我都快两月了还是under reviewCXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…CXK 2020-04-11 00:00:00 发表: 40天了还是分配编辑有比我还久的嘛…, beContent=CXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0635277719, createdName=148378a5m85暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=)]

2020-09-23 ms9000000365593010

审稿速度:2.0 | 投稿命中率:50.0
经验分享：半年了，今天被接收，真的好激动

87 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573717, encodeId=26d75e3717b9, content=我被拒稿了，很闹心，二修被拒稿的811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？811056778 2019-07-15 00:00:00 发表: 有被拒稿的吗？大家都under review 很久吗？, beContent=811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c2453714, createdName=123fdc7am51暂无昵称, createdTime=Tue Jul 16 00:00:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053539, encodeId=5e40105353926, content=审稿速度:6.0 | 投稿命中率:75.0 | 版面费用:3025.0 偏重的研究方向：肿瘤 经验分享：under review 的时间比较长，我的4个月。 然后3个reviwers中一个很mean，另外两个很nice。最后小修的时候直接没有返回第一个review的意见。 感觉过了第一次riview后就比较有希望，编辑整体对中国的作者还挺nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd391571598, createdName=cookie97_02, createdTime=Tue Sep 21 17:56:32 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861880, encodeId=5e738618805e, content=审稿速度:1.0 经验分享：杂志主编是杜克大学魏庆义教授，之前投过三次，有最后被专科顶级期刊（3.8分）接收的文章，每次都是投完第二天就显示under review，然后2-3周后reject且没有外审意见，这本杂志上面文章整体质量参差不齐，好几篇与外科相关的公共数据库文章硬伤很明显，但居然都能被接收，不知道是不是因为想赚取版面费，毕竟版面费很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470b5414019, createdName=ms8494960720180498, createdTime=Sun Jun 14 20:19:48 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589120, encodeId=91e55891204e, content=pending decision快2周了是还在找审稿人吗..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba91646015, createdName=凱当以慷, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887784, encodeId=bc3888e784c6, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：半年了，今天被接收，真的好激动, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66315412610, createdName=ms9000000365593010, createdTime=Wed Sep 23 22:03:59 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943952, encodeId=ebf8943952fc, content=Cancer Medicine期刊近5年发文量先下降再上涨，2016年仅有三百多篇，2017年有所缩篇至200篇+，2018年有大幅度扩篇发文量为590篇，2019年持续大幅度扩篇突破800篇+，2020年与2019年基本持平。其他信息：中国发文占比约为（51 %），去年国人发文占比为290/834(34.8%)。自引率 Cancer Medicine近五年自引率均控制在2.1%以下，2016年为1.3%，2017年为1.3%，2018年为1.9%，2019年自引率为2.1%，2020年自引率为0.8%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Sat Feb 27 15:29:10 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588880, encodeId=ed82588880e7, content=请问pending editor assignment是啥，要持续多久137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, beContent=137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803209, encodeId=447a803209d1, content=刚中一个不容易！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sat Jul 18 18:33:54 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801120, encodeId=8d69801120c5, content=共同通讯怎么选择呀？网站上面只能选一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhNNGfbGSN7wmcNz2pib2uha6Ao0k08eBAYg1j1K239eYgsrXibWPvG9SMo9UY32HXlSHgibarsFKkQ/132, createdBy=8b052569732, createdName=305263495_85429342, createdTime=Fri Jul 03 22:54:07 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589182, encodeId=3c765891821f, content=我都快两月了还是under reviewCXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…CXK 2020-04-11 00:00:00 发表: 40天了还是分配编辑有比我还久的嘛…, beContent=CXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0635277719, createdName=148378a5m85暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=)]

2021-02-27 健康达人

Cancer Medicine期刊近5年发文量先下降再上涨，2016年仅有三百多篇，2017年有所缩篇至200篇+，2018年有大幅度扩篇发文量为590篇，2019年持续大幅度扩篇突破800篇+，2020年与2019年基本持平。其他信息：中国发文占比约为（51 %），去年国人发文占比为290/834(34.8%)。自引率 Cancer Medicine近五年自引率均控制在2.1%以下，2016年为1.3%，2017年为1.3%，2018年为1.9%，2019年自引率为2.1%，2020年自引率为0.8%。

111 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573717, encodeId=26d75e3717b9, content=我被拒稿了，很闹心，二修被拒稿的811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？811056778 2019-07-15 00:00:00 发表: 有被拒稿的吗？大家都under review 很久吗？, beContent=811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c2453714, createdName=123fdc7am51暂无昵称, createdTime=Tue Jul 16 00:00:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053539, encodeId=5e40105353926, content=审稿速度:6.0 | 投稿命中率:75.0 | 版面费用:3025.0 偏重的研究方向：肿瘤 经验分享：under review 的时间比较长，我的4个月。 然后3个reviwers中一个很mean，另外两个很nice。最后小修的时候直接没有返回第一个review的意见。 感觉过了第一次riview后就比较有希望，编辑整体对中国的作者还挺nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd391571598, createdName=cookie97_02, createdTime=Tue Sep 21 17:56:32 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861880, encodeId=5e738618805e, content=审稿速度:1.0 经验分享：杂志主编是杜克大学魏庆义教授，之前投过三次，有最后被专科顶级期刊（3.8分）接收的文章，每次都是投完第二天就显示under review，然后2-3周后reject且没有外审意见，这本杂志上面文章整体质量参差不齐，好几篇与外科相关的公共数据库文章硬伤很明显，但居然都能被接收，不知道是不是因为想赚取版面费，毕竟版面费很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470b5414019, createdName=ms8494960720180498, createdTime=Sun Jun 14 20:19:48 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589120, encodeId=91e55891204e, content=pending decision快2周了是还在找审稿人吗..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba91646015, createdName=凱当以慷, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887784, encodeId=bc3888e784c6, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：半年了，今天被接收，真的好激动, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66315412610, createdName=ms9000000365593010, createdTime=Wed Sep 23 22:03:59 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943952, encodeId=ebf8943952fc, content=Cancer Medicine期刊近5年发文量先下降再上涨，2016年仅有三百多篇，2017年有所缩篇至200篇+，2018年有大幅度扩篇发文量为590篇，2019年持续大幅度扩篇突破800篇+，2020年与2019年基本持平。其他信息：中国发文占比约为（51 %），去年国人发文占比为290/834(34.8%)。自引率 Cancer Medicine近五年自引率均控制在2.1%以下，2016年为1.3%，2017年为1.3%，2018年为1.9%，2019年自引率为2.1%，2020年自引率为0.8%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Sat Feb 27 15:29:10 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588880, encodeId=ed82588880e7, content=请问pending editor assignment是啥，要持续多久137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, beContent=137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803209, encodeId=447a803209d1, content=刚中一个不容易！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sat Jul 18 18:33:54 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801120, encodeId=8d69801120c5, content=共同通讯怎么选择呀？网站上面只能选一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhNNGfbGSN7wmcNz2pib2uha6Ao0k08eBAYg1j1K239eYgsrXibWPvG9SMo9UY32HXlSHgibarsFKkQ/132, createdBy=8b052569732, createdName=305263495_85429342, createdTime=Fri Jul 03 22:54:07 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589182, encodeId=3c765891821f, content=我都快两月了还是under reviewCXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…CXK 2020-04-11 00:00:00 发表: 40天了还是分配编辑有比我还久的嘛…, beContent=CXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0635277719, createdName=148378a5m85暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=)]

2020-04-15 147c079dm30(暂无昵称)

请问pending editor assignment是啥，要持续多久137****5628暂无昵称 2020-04-11 00:00:00 发表:
请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o

137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o

113 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573717, encodeId=26d75e3717b9, content=我被拒稿了，很闹心，二修被拒稿的811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？811056778 2019-07-15 00:00:00 发表: 有被拒稿的吗？大家都under review 很久吗？, beContent=811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c2453714, createdName=123fdc7am51暂无昵称, createdTime=Tue Jul 16 00:00:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053539, encodeId=5e40105353926, content=审稿速度:6.0 | 投稿命中率:75.0 | 版面费用:3025.0 偏重的研究方向：肿瘤 经验分享：under review 的时间比较长，我的4个月。 然后3个reviwers中一个很mean，另外两个很nice。最后小修的时候直接没有返回第一个review的意见。 感觉过了第一次riview后就比较有希望，编辑整体对中国的作者还挺nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd391571598, createdName=cookie97_02, createdTime=Tue Sep 21 17:56:32 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861880, encodeId=5e738618805e, content=审稿速度:1.0 经验分享：杂志主编是杜克大学魏庆义教授，之前投过三次，有最后被专科顶级期刊（3.8分）接收的文章，每次都是投完第二天就显示under review，然后2-3周后reject且没有外审意见，这本杂志上面文章整体质量参差不齐，好几篇与外科相关的公共数据库文章硬伤很明显，但居然都能被接收，不知道是不是因为想赚取版面费，毕竟版面费很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470b5414019, createdName=ms8494960720180498, createdTime=Sun Jun 14 20:19:48 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589120, encodeId=91e55891204e, content=pending decision快2周了是还在找审稿人吗..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba91646015, createdName=凱当以慷, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887784, encodeId=bc3888e784c6, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：半年了，今天被接收，真的好激动, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66315412610, createdName=ms9000000365593010, createdTime=Wed Sep 23 22:03:59 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943952, encodeId=ebf8943952fc, content=Cancer Medicine期刊近5年发文量先下降再上涨，2016年仅有三百多篇，2017年有所缩篇至200篇+，2018年有大幅度扩篇发文量为590篇，2019年持续大幅度扩篇突破800篇+，2020年与2019年基本持平。其他信息：中国发文占比约为（51 %），去年国人发文占比为290/834(34.8%)。自引率 Cancer Medicine近五年自引率均控制在2.1%以下，2016年为1.3%，2017年为1.3%，2018年为1.9%，2019年自引率为2.1%，2020年自引率为0.8%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Sat Feb 27 15:29:10 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588880, encodeId=ed82588880e7, content=请问pending editor assignment是啥，要持续多久137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, beContent=137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803209, encodeId=447a803209d1, content=刚中一个不容易！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sat Jul 18 18:33:54 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801120, encodeId=8d69801120c5, content=共同通讯怎么选择呀？网站上面只能选一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhNNGfbGSN7wmcNz2pib2uha6Ao0k08eBAYg1j1K239eYgsrXibWPvG9SMo9UY32HXlSHgibarsFKkQ/132, createdBy=8b052569732, createdName=305263495_85429342, createdTime=Fri Jul 03 22:54:07 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589182, encodeId=3c765891821f, content=我都快两月了还是under reviewCXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…CXK 2020-04-11 00:00:00 发表: 40天了还是分配编辑有比我还久的嘛…, beContent=CXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0635277719, createdName=148378a5m85暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=)]

2020-07-18 145d9400m83暂无昵称

刚中一个不容易！

59 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573717, encodeId=26d75e3717b9, content=我被拒稿了，很闹心，二修被拒稿的811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？811056778 2019-07-15 00:00:00 发表: 有被拒稿的吗？大家都under review 很久吗？, beContent=811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c2453714, createdName=123fdc7am51暂无昵称, createdTime=Tue Jul 16 00:00:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053539, encodeId=5e40105353926, content=审稿速度:6.0 | 投稿命中率:75.0 | 版面费用:3025.0 偏重的研究方向：肿瘤 经验分享：under review 的时间比较长，我的4个月。 然后3个reviwers中一个很mean，另外两个很nice。最后小修的时候直接没有返回第一个review的意见。 感觉过了第一次riview后就比较有希望，编辑整体对中国的作者还挺nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd391571598, createdName=cookie97_02, createdTime=Tue Sep 21 17:56:32 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861880, encodeId=5e738618805e, content=审稿速度:1.0 经验分享：杂志主编是杜克大学魏庆义教授，之前投过三次，有最后被专科顶级期刊（3.8分）接收的文章，每次都是投完第二天就显示under review，然后2-3周后reject且没有外审意见，这本杂志上面文章整体质量参差不齐，好几篇与外科相关的公共数据库文章硬伤很明显，但居然都能被接收，不知道是不是因为想赚取版面费，毕竟版面费很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470b5414019, createdName=ms8494960720180498, createdTime=Sun Jun 14 20:19:48 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589120, encodeId=91e55891204e, content=pending decision快2周了是还在找审稿人吗..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba91646015, createdName=凱当以慷, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887784, encodeId=bc3888e784c6, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：半年了，今天被接收，真的好激动, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66315412610, createdName=ms9000000365593010, createdTime=Wed Sep 23 22:03:59 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943952, encodeId=ebf8943952fc, content=Cancer Medicine期刊近5年发文量先下降再上涨，2016年仅有三百多篇，2017年有所缩篇至200篇+，2018年有大幅度扩篇发文量为590篇，2019年持续大幅度扩篇突破800篇+，2020年与2019年基本持平。其他信息：中国发文占比约为（51 %），去年国人发文占比为290/834(34.8%)。自引率 Cancer Medicine近五年自引率均控制在2.1%以下，2016年为1.3%，2017年为1.3%，2018年为1.9%，2019年自引率为2.1%，2020年自引率为0.8%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Sat Feb 27 15:29:10 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588880, encodeId=ed82588880e7, content=请问pending editor assignment是啥，要持续多久137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, beContent=137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803209, encodeId=447a803209d1, content=刚中一个不容易！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sat Jul 18 18:33:54 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801120, encodeId=8d69801120c5, content=共同通讯怎么选择呀？网站上面只能选一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhNNGfbGSN7wmcNz2pib2uha6Ao0k08eBAYg1j1K239eYgsrXibWPvG9SMo9UY32HXlSHgibarsFKkQ/132, createdBy=8b052569732, createdName=305263495_85429342, createdTime=Fri Jul 03 22:54:07 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589182, encodeId=3c765891821f, content=我都快两月了还是under reviewCXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…CXK 2020-04-11 00:00:00 发表: 40天了还是分配编辑有比我还久的嘛…, beContent=CXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0635277719, createdName=148378a5m85暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=)]

2020-07-03 305263495_85429342

共同通讯怎么选择呀？网站上面只能选一个

64 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573717, encodeId=26d75e3717b9, content=我被拒稿了，很闹心，二修被拒稿的811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？811056778 2019-07-15 00:00:00 发表: 有被拒稿的吗？大家都under review 很久吗？, beContent=811056778 2019-07-15 发表:: 有被拒稿的吗？大家都under review 很久吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c2453714, createdName=123fdc7am51暂无昵称, createdTime=Tue Jul 16 00:00:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053539, encodeId=5e40105353926, content=审稿速度:6.0 | 投稿命中率:75.0 | 版面费用:3025.0 偏重的研究方向：肿瘤 经验分享：under review 的时间比较长，我的4个月。 然后3个reviwers中一个很mean，另外两个很nice。最后小修的时候直接没有返回第一个review的意见。 感觉过了第一次riview后就比较有希望，编辑整体对中国的作者还挺nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd391571598, createdName=cookie97_02, createdTime=Tue Sep 21 17:56:32 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861880, encodeId=5e738618805e, content=审稿速度:1.0 经验分享：杂志主编是杜克大学魏庆义教授，之前投过三次，有最后被专科顶级期刊（3.8分）接收的文章，每次都是投完第二天就显示under review，然后2-3周后reject且没有外审意见，这本杂志上面文章整体质量参差不齐，好几篇与外科相关的公共数据库文章硬伤很明显，但居然都能被接收，不知道是不是因为想赚取版面费，毕竟版面费很高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470b5414019, createdName=ms8494960720180498, createdTime=Sun Jun 14 20:19:48 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589120, encodeId=91e55891204e, content=pending decision快2周了是还在找审稿人吗..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba91646015, createdName=凱当以慷, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887784, encodeId=bc3888e784c6, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：半年了，今天被接收，真的好激动, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66315412610, createdName=ms9000000365593010, createdTime=Wed Sep 23 22:03:59 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943952, encodeId=ebf8943952fc, content=Cancer Medicine期刊近5年发文量先下降再上涨，2016年仅有三百多篇，2017年有所缩篇至200篇+，2018年有大幅度扩篇发文量为590篇，2019年持续大幅度扩篇突破800篇+，2020年与2019年基本持平。其他信息：中国发文占比约为（51 %），去年国人发文占比为290/834(34.8%)。自引率 Cancer Medicine近五年自引率均控制在2.1%以下，2016年为1.3%，2017年为1.3%，2018年为1.9%，2019年自引率为2.1%，2020年自引率为0.8%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Sat Feb 27 15:29:10 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588880, encodeId=ed82588880e7, content=请问pending editor assignment是啥，要持续多久137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, beContent=137****5628暂无昵称 2020-04-11 00:00:00 发表: 请问后来变回under review 后还有审稿意见吗？还是说直接又变成pending descion的？我现在就是修回后直接变pending descion ，两周了今天发现变成了under review难过o(╥﹏╥)o, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803209, encodeId=447a803209d1, content=刚中一个不容易！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24355093072, createdName=145d9400m83暂无昵称, createdTime=Sat Jul 18 18:33:54 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801120, encodeId=8d69801120c5, content=共同通讯怎么选择呀？网站上面只能选一个, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhNNGfbGSN7wmcNz2pib2uha6Ao0k08eBAYg1j1K239eYgsrXibWPvG9SMo9UY32HXlSHgibarsFKkQ/132, createdBy=8b052569732, createdName=305263495_85429342, createdTime=Fri Jul 03 22:54:07 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589182, encodeId=3c765891821f, content=我都快两月了还是under reviewCXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…CXK 2020-04-11 00:00:00 发表: 40天了还是分配编辑有比我还久的嘛…, beContent=CXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0635277719, createdName=148378a5m85暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=)]

2020-04-18 148378a5m85暂无昵称

我都快两月了还是under reviewCXK 2020-04-11 发表::
40天了还是分配编辑有比我还久的嘛…CXK 2020-04-11 00:00:00 发表:
40天了还是分配编辑有比我还久的嘛…

CXK 2020-04-11 发表:: 40天了还是分配编辑有比我还久的嘛…

76 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务